Lnc2Cancer

Experimentally Supported Human LncRNA and Cancer Associations Database

LncRNA centric

Cancer centric

Advanced search

Drug resistant

Circulating

Prognosis

Detail


   LncRNA Name HOXA11-AS
   Synonyms HOXA11-AS, HOXA-AS5, HOXA11-AS1, HOXA11AS, HOXA11S, NCRNA00076
   Region GRCh38_7:27184518-27189293    Sequence
   Ensembl ENSG00000240990
   RefSeq NR_002795
   Circulating
   Drug-resisitant
   Prognostic
   MiRNA
   Variant
   TF
   Methylation
   Cancer Name hepatocellular carcinoma
   ICD-0-3 C22.0  M8170/3
   Methods qPCR, Western blot etc.
   Sample hepatocellular carcinoma tissues, cell lines(Hep3B, SMMC-7721, MHCC97-H, BEL-7402 and HL-7702)
   Expression Pattern up-regulated
   Function Description

HOXA11-AS expression was up-regulated in the HCC tissues,and the higher expression of HOXA11-AS was associated with the advanced stage in the HCC samples. In addition,the expression of HOXA11-AS was up-regulated in HCC cell lines compared with normal liver cell lines. Ectopic expression of miR-214-3p suppressed HCC cell proliferation and invasion.Furthermore,we indicated that overexpression of HOXA11-AS decreased the miR-214-3p expression and the expression of miR-214-3p was negatively related with the HOXA11-AS expression in HCC samples. Ectopic expression of HOXA11-AS increased HCC proliferation and invasion and induced EMT through inhibiting miR-214-3p expression.These data suggested that HOXA11-AS/miR-214-3p axis was responsible for development of HCC.We ndemonstrated that miR-214-3p expression was down-regulated in the HCC tissues and the expression of miR-214-3p was negatively correlated with the expression of HOXA11-AS.

   Pubmed ID 29761918
   Year 2018
   Title LncRNA HOXA11-AS promotes hepatocellular carcinoma progression by repressing miR-214-3p.
   External Links
   Links for  HOXA11-AS GenBank       HGNC       lncrnadb       Noncode
   Links for  hepatocellular carcinoma Omim       Cosmic

CopyRight © College of Bioinformatics Science and Technology, Harbin Medical University, China.